








, and

133. A pharmaceutical composition, comprising a compound of any one of claims 1-132; and a pharmaceutically acceptable carrier.

134. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for parenteral administration.

135. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for oral administration.

136. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for the prophylactic or therapeutic treatment of a disease or condition characterized by unwanted plasma kallikrein activity.

137. A method of treating or preventing a disease or condition characterized by unwanted plasma kallikrein activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-132.

138. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease,

diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

139. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

140. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

141. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is stroke.





142. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is reperfusion injury.

143. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is acute myocardial infarction.

144. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hemorrhage.

145. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is blood loss during cardiopulmonary bypass.

146. The method of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, and proliferative retinopathy.

, and .

133. A pharmaceutical composition, comprising a compound of any one of claims 1-132; and a pharmaceutically acceptable carrier.

134. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for parenteral administration.

135. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for oral administration.

136. The pharmaceutical composition of claim 133, wherein the pharmaceutical composition is formulated for the prophylactic or therapeutic treatment of a disease or condition characterized by unwanted plasma kallikrein activity.

137. A compound of any one of claims 1-132 for use in the treatment or prevention of a disease or condition characterized by unwanted plasma kallikrein activity.

138. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration,

proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

139. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is angioedema.

140. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hereditary angioedema.

141. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is stroke.

142. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is reperfusion injury.

143. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is acute myocardial infarction.

144. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is hemorrhage.

145. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is blood loss during cardiopulmonary bypass.

146. The compound of claim 137, wherein the disease or condition characterized by unwanted plasma kallikrein activity is selected from the group consisting of retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, and proliferative retinopathy.